Oxford Finance closed a US $20MM senior secured term loan with Cerapedics. Proceeds will support commercialization of i-FACTOR Peptide Enhanced Bone Graft for Anterior Cervical Discectomy and Fusion (ACDF) and fund an FDA study on its application in Transforaminal Lumbar Interbody Fusion.
i-FACTOR is reported to be the first and only FDA-approved product for ACDF and the first device to demonstrate superiority vs. autograft.
Oxford Finance closed a US $20MM senior secured term loan with Cerapedics. Proceeds will support commercialization of i-FACTOR Peptide Enhanced Bone Graft for Anterior Cervical Discectomy and Fusion (ACDF) and fund an FDA study on its application in Transforaminal Lumbar Interbody Fusion.
i-FACTOR is reported to be the first and...
Oxford Finance closed a US $20MM senior secured term loan with Cerapedics. Proceeds will support commercialization of i-FACTOR Peptide Enhanced Bone Graft for Anterior Cervical Discectomy and Fusion (ACDF) and fund an FDA study on its application in Transforaminal Lumbar Interbody Fusion.
i-FACTOR is reported to be the first and only FDA-approved product for ACDF and the first device to demonstrate superiority vs. autograft.
Copy to clipboard 
